酸酶6型通过激活PI3K/AKT通路促进子宫内膜癌的进展
Qingling Lin1,2, Xiaolei Liang3,4, Liangjian Ma1
1The First Clinical Medical College of Lanzhou University, Lanzhou, China.
Molecular biology reports
|June 27, 2025
概括
酸酶6型 (ACP6) 通过激活PI3K/AKT通路,促进子宫内膜癌 (EC) 的生长和转移. 针对ACP6可能为EC治疗提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 子宫内膜癌 (EC) 是女性死亡的主要原因之一.
- 酸酸酶6型 (ACP6) 与癌症进展有关,但其在EC中的作用尚不清楚.
研究的目的:
- 研究ACP6在子宫内膜癌中的作用.
- 探索EC中ACP6的潜在分子机制.
主要方法:
- 分析了癌症基因组图谱 (TCGA) 的RNA-Seq数据,用于ACP6表达.
- 通过使用RT-qPCR和Western blot评估了ACP6水平.
- 评估了ACP6操纵对EC细胞增殖,迁移和入侵的 in vitro 和 in vivo 影响.
主要成果:
- 与正常组织相比,EC组织中ACP6的表达显著增加.
- 过度表达ACP6增强了EC细胞的增殖,迁移和入侵.
- 在体内抑制瘤生长,并抑制PI3K/AKT通路.
结论:
- 通过激活PI3K/AKT通路,ACP6促进了EC的发展和进步.
- ACP6是治疗子宫内膜癌的潜在治疗点.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Amplifying Signals via Enzymatic Cascade
9.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
9.3K
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K


